Curie.Bio, the biotech accelerator and investment firm started by Alexis Borisy and Zach Weinberg, has raised another $340 million to invest in startups.
Borisy and Weinberg’s firm was created to upend the biotech financing model, offering both capital and expert assistance to founders seeking on option outside of traditional VC funding. The idea has resonated with venture capitalists — several of whom have invested in Curie.Bio — and startups. Since 2022, Curie.Bio has received some 4,000 applications. It has invested in 26 startups, giving it a less than 1% acceptance rate.
Curie.Bio’s new fund will help the organization double its investing over the next two years: The aim is to invest in between 15 and 20 biotechs this year and up to 25 companies in 2026, the founders told STAT exclusively.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
